A crystalline form of a benzothiophene-substituted fused ring compound and a method of making the same
By preparing multiple crystal forms of the KRAS G12D inhibitor, the stability and crystallization problems of amorphous compounds were solved, and the stability, production, and storage of the compounds were improved, making them suitable for clinical applications.
CN119684316BActive Publication Date: 2026-06-16SUZHOU SUNCADIA BIOPHARM CO LTD +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SUZHOU SUNCADIA BIOPHARM CO LTD
- Filing Date
- 2024-12-17
- Publication Date
- 2026-06-16
Smart Images
Figure CN119684316B_ABST
Abstract
The present disclosure relates to a crystalline form of a benzothiophene-substituted fused ring compound and a preparation method thereof. Specifically, the present disclosure provides a crystal form A and a crystal form D of 2-amino-7-fluoro-4-((5S,5aS,6S,9R)-1-fluoro-12-((1-((4-(fluoromethylidene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-methyl-5a,6,7,8,9,10-hexahydro-5H-4-oxa-3,10a,11,13,14-pentaaza-6,9-methanonaphtho[1,8-ab]heptalen-2-yl)benzo[b]thiophene-3-carbonitrile, which has good stability and can be better used for clinical treatment.
Need to check novelty before this filing date? Find Prior Art